Vahid Naini

3.3k total citations · 1 hit paper
21 papers, 1.2k citations indexed

About

Vahid Naini is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Vahid Naini has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 12 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Surgery. Recurrent topics in Vahid Naini's work include Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Cancer, Lipids, and Metabolism (7 papers). Vahid Naini is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Cancer, Lipids, and Metabolism (7 papers). Vahid Naini collaborates with scholars based in United States, United Kingdom and Italy. Vahid Naini's co-authors include Mustafa Özgüroğlu, Kris Deprince, Jinhui Li, Neeraj Agarwal, Dingwei Ye, Axel S. Merseburger, Álvaro Juárez Soto, Andrea Juliana Gomes, Kim N. and Simon Chowdhury and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Vahid Naini

20 papers receiving 1.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

2019 891 citations Kim N., Neeraj Agarwal et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vahid Naini United States	8	1.1k	417	357	244	191	21	1.2k
Álvaro Juárez Soto Spain	8	1.1k 1.0×	379 0.9×	345 1.0×	222 0.9×	201 1.1×	44	1.2k
Sharon McCarthy United States	8	962 0.9×	341 0.8×	326 0.9×	217 0.9×	175 0.9×	28	1.1k
Andrea Juliana Gomes United States	8	1.4k 1.3×	496 1.2×	450 1.3×	336 1.4×	245 1.3×	24	1.5k
Kris Deprince United States	7	948 0.9×	333 0.8×	312 0.9×	252 1.0×	167 0.9×	15	1.2k
Iris Kuss Germany	12	1.1k 1.0×	400 1.0×	400 1.1×	251 1.0×	224 1.2×	40	1.3k
Per Rathenborg Denmark	11	923 0.9×	308 0.7×	325 0.9×	309 1.3×	182 1.0×	18	1.1k
Albertas Ulys Lithuania	16	1.1k 1.0×	337 0.8×	459 1.3×	323 1.3×	235 1.2×	64	1.4k
Youyi Shu United States	9	827 0.8×	263 0.6×	290 0.8×	176 0.7×	146 0.8×	14	1.0k
Murilo Luz Brazil	7	952 0.9×	303 0.7×	324 0.9×	199 0.8×	175 0.9×	34	1.1k
Maria De Santis Austria	9	1.2k 1.2×	474 1.1×	253 0.7×	288 1.2×	109 0.6×	25	1.4k

Countries citing papers authored by Vahid Naini

Since Specialization

Citations

This map shows the geographic impact of Vahid Naini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vahid Naini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vahid Naini more than expected).

Fields of papers citing papers by Vahid Naini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vahid Naini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vahid Naini. The network helps show where Vahid Naini may publish in the future.

Co-authorship network of co-authors of Vahid Naini

This figure shows the co-authorship network connecting the top 25 collaborators of Vahid Naini. A scholar is included among the top collaborators of Vahid Naini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vahid Naini. Vahid Naini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Daneshmand, Siamak, Renata Zaucha, James W.F. Catto, et al.. (2025). Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. European Urology. 89(2). 165–173.

Daneshmand, Siamak, Renata Zaucha, Nikhil Vasdev, et al.. (2024). MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS. Urologic Oncology Seminars and Original Investigations. 42. S58–S58. 1 indexed citations

Catto, James W.F., Ben Tran, Viraj A. Master, et al.. (2023). Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 2 interim analysis results.. Journal of Clinical Oncology. 41(6_suppl). 503–503. 7 indexed citations

Daneshmand, Siamak, Renata Zaucha, Benjamin A. Gartrell, et al.. (2023). Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non–muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis.. Journal of Clinical Oncology. 41(6_suppl). 504–504. 5 indexed citations

Kalebasty, Arash Rezazadeh, David J. Benjamin, Yohann Loriot, et al.. (2022). Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study. European Urology Open Science. 47. 48–57. 4 indexed citations

Rezazadeh, Arash, Yohann Loriot, Arlene O. Siefker‐Radtke, et al.. (2020). 757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status. Annals of Oncology. 31. S586–S587. 5 indexed citations

N., Kim, Neeraj Agarwal, Anders Bjartell, et al.. (2019). First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology. 37(15_suppl). 5006–5006. 1 indexed citations

Agarwal, Neeraj, Kelly McQuarrie, Anders Bjartell, et al.. (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. The Lancet Oncology. 20(11). 1518–1530. 69 indexed citations

Chi, K.N., Shibu Thomas, Neeraj Agarwal, et al.. (2019). Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN. Annals of Oncology. 30. v347–v348. 6 indexed citations

10.

Agarwal, Neeraj, Kelly McQuarrie, Anders Bjartell, et al.. (2019). Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC). Annals of Oncology. 30. v330–v331. 1 indexed citations

11.

N., Kim, Neeraj Agarwal, Anders Bjartell, et al.. (2019). Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 381(1). 13–24. 891 indexed citations breakdown →

12.

Ye, Dingwei, Yong Huang, Fangjian Zhou, et al.. (2017). A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian journal of urology. 4(2). 75–85. 24 indexed citations

13.

Chi, K.N., S. Chowdhury, Piotr Radziszewski, et al.. (2016). TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. 27. vi265–vi265. 8 indexed citations

14.

Morris, Michael J., Arturo Molina, Eric J. Small, et al.. (2015). Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. Journal of Clinical Oncology. 33(12). 1356–1363. 86 indexed citations

15.

Sternberg, Cora N., Daniel Castellano, Gedske Daugaard, et al.. (2014). Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. The Lancet Oncology. 15(11). 1263–1268. 40 indexed citations

16.

Hamilton, Robert J., Jinhui Li, Vahid Naini, et al.. (2014). Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 32(15_suppl). e16045–e16045. 5 indexed citations

17.

Ryan, Charles J., Karim Fizazi, K. Miller, et al.. (2014). Final Overall Survival (Os) Analysis of Cou-Aa-302, a Randomized Phase 3 Study of Abiraterone Acetate (Aa) in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts) Without Prior Chemotherapy. Annals of Oncology. 25. iv255–iv255. 26 indexed citations

18.

Castellano, Daniel, Sergio Bracarda, Marcello Tucci, et al.. (2014). Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. Annals of Oncology. 25. iv269–iv269. 1 indexed citations

19.

George, Daniel J., Tracy McGowan, Gedske Daugaard, et al.. (2013). Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy.. Journal of Clinical Oncology. 31(15_suppl). 5059–5059. 1 indexed citations

20.

Breneman, Debra, et al.. (2007). Phase II clinical trial of bexarotene gel 1% in psoriasis.. PubMed. 6(5). 501–6. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact